Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2018

View Archived Issues

Eisai reviews milestones of third quarter of fiscal 2017

Pembrolizumab plus rhuGM-CSF found safe in patients with advanced biliary cancer

FDA gives RMAT designation to Capricor's CAP-1002 for DMD

Dose modification on MM-398 plus 5-FU/LV does not impact survival

Silver Creek Pharmaceuticals completes financing to advance SGF-1

IND for anti-PD-L1 antibody STI-A1015 cleared in South Korea

Mitsubishi Tanabe Pharma reviews developments of third quarter of fiscal 2017

Positive topline phase III results from ACHIEVE I study of ubrogepant

Topline data presented from phase II study of NGM-282 in primary sclerosing cholangitis

Servier and ImmunoQure to collaborate on the development of an interferon-alpha human autoantibody

Zogenix's ZX-008 granted FDA breakthrough therapy designation

First patient treated in phase II study of Imprime PGG in combination with Keytruda

Novel PAR-4 antagonists discovered at Bristol-Myers Squibb

Bavarian Nordic reports results from phase III pivotal study of smallpox vaccine

Actinium to study Actimab-A with CLAG-M in relapsed or refractory AML

Lifesci Pharmaceuticals discloses new plasma kallikrein inhibitors

Bioway describes novel PI3Kdelta/PI3Kgamma inhibitors

AstraZeneca's application to expand Tagrisso indication in Japan granted priority review

Novel 5-HT7 receptor agonists identified at the Institute of Pharmacology

Astellas divulges new melanocortin MC4 receptor agonists

Roche profiles pipeline progress of fourth quarter 2017

Synairgen initiates phase II trial of inhaled SNG-001 in COPD

STAT3 shown as potential therapeutic target for gastroenteropancreatic neuroendocrine tumors

NetVation DL Medicine, Pfizer enter research collaboration

ContraVir Pharmaceuticals' TXL safe, well tolerated in phase I study

Durvalumab/tremelimumab/nab-paclitaxel/gemcitabine regimen well tolerated in metastatic PDAC

Imugene reports early data from trial of IMU-131 in metastatic gastric cancer

Janssen and Theravance establish collaboration on TD-1473 for inflammatory intestinal diseases

Targovax completes safety lead-in of phase I/II trial of ONCOS-102 in mesothelioma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...